Literature DB >> 9264393

Germline configuration of nfkb2, c-rel and bcl3 in childhood acute lymphoblastic leukemia (ALL).

S Liptay1, T Seriu, C R Bartram, R M Schmid.   

Abstract

The well-known family of NF-kappaB/Rel transcription factors is a central regulator of growth, differentiation and apoptosis in hematopoietic cell lineages. There is increasing evidence for their role in malignant transformation, especially in lymphomas. To study the possible involvement of NF-kappaB/Rel genes in the development of pediatric acute lymphoblastic leukemia (ALL), DNA samples from 140 patients were examined by Southern blot analysis. All samples revealed germline configuration of nfkb2, c-rel, and bcl3, indicating that structural alterations of these members of the NF-kappaB/Rel family are extremely rare, if existing at all in childhood ALL.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9264393     DOI: 10.1038/sj.leu.2400778

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  5 in total

Review 1.  New insights into the role of nuclear factor-kappaB in cell growth regulation.

Authors:  F Chen; V Castranova; X Shi
Journal:  Am J Pathol       Date:  2001-08       Impact factor: 4.307

Review 2.  NF-kappaB/Rel transcriptional pathway: implications in pancreatic cancer.

Authors:  Hana Algül; Guido Adler; Roland M Schmid
Journal:  Int J Gastrointest Cancer       Date:  2002

Review 3.  Molecular pharmacodynamics in childhood leukemia.

Authors:  R Pieters; M L den Boer
Journal:  Int J Hematol       Date:  2003-12       Impact factor: 2.490

4.  Nuclear factor kappa B: a marker of chemotherapy for human stage IV gastric carcinoma.

Authors:  You-Ming Long; Sheng Ye; Jian Rong; Wen-Rui Xie
Journal:  World J Gastroenterol       Date:  2008-08-14       Impact factor: 5.742

5.  Nuclear localisation of nuclear factor-kappaB transcription factors in prostate cancer: an immunohistochemical study.

Authors:  L Lessard; L R Bégin; M E Gleave; A-M Mes-Masson; F Saad
Journal:  Br J Cancer       Date:  2005-10-31       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.